Pharmaceutical composition for treating asthma

A composition and drug technology, applied in the field of medicine, can solve the problems of reduced drug efficacy, inability to cure asthma, low immunity, etc., and achieve the effects of obvious effects, improvement of lung tissue lesions, and reduction of levels

Inactive Publication Date: 2017-09-15
解益新
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, glucocorticoids and β2-receptor agonists are the first-choice drugs to control asthma attacks in clinical practice, but they cannot cure asthma, and repeated use will cause side effects such as reduced drug efficacy, osteoporosis, and low immunity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating asthma
  • Pharmaceutical composition for treating asthma
  • Pharmaceutical composition for treating asthma

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0017] The characterization of experimental example 1 medicine of the present invention

[0018]

[0019] 1 H-NMR (300MHz, CDCl 3 )δ8.94-8.76 (m, 2H), 8.29 (d, J = 4.8Hz, 2H), 7.67 (d, J = 1.7Hz, 1H), 6.53 (t, J = 4.8Hz, 1H), 6.37 ( tt,J=3.1,1.5Hz,1H),5.30(d,J=7.9Hz,1H),4.87(dt,J=7.5,3.6Hz,1H),4.43(q,J=2.8Hz,2H), 4.02(t, J=5.5Hz, 3H), 2.68(dqd, J=6.0, 3.4, 3.0, 1.8Hz, 2H), 2.35-2.11(m, 2H), 2.07-1.84(m, 6H); ESMS( M+H + ) = 404.2.

experiment example 2

[0020] The effect of experimental example 2 medicine treatment asthma of the present invention

[0021] Male SD rats aged 6-8 weeks, SPF grade, and weighing 200±20 g were divided into a normal group of 10 and a model group according to the random number table method. The above-mentioned rats were kept in the same room and divided into cages, 5 in each cage, fed under sterile conditions, and had free access to drinking water.

[0022] Animal grouping and model preparation

[0023] Rats except the normal group were established with asthma model: on the 1st day and the 8th day, 1ml of antigen solution (containing ovalbumin 100mg, aluminum hydroxide dry powder 200mg, inactivated Bacillus pertussis 5×10 9 One, dissolved in 1ml of normal saline), on the 15th day, nebulized inhalation of 30ml of 5% ovalbumin prepared with normal saline was stimulated, once a day, 30min each time, for 14 days in a row.

[0024] Normal group: On the 1st day and the 8th day, 1ml of normal saline was i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating asthma. The pharmaceutical composition has an innovative structure: the medicine of the invention has obvious effects in treating asthma, aims at the pathogenesis of asthma, has a clear purpose, and improves the lung tissue lesions of asthmatic patients. , reduce the level of related factors in lung tissue, and can be used as an innovative drug for the clinical treatment of asthma.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to a pharmaceutical composition for treating asthma. Background technique [0002] Bronchial asthma is a chronic airway inflammatory disease involving eosinophil infiltration, T lymphocytes, mast cells, airway epithelial cells and other inflammatory cells and cytokines, manifested by eosinophil-based inflammatory cells Pathological features such as infiltration, airway hyperresponsiveness, and airway remodeling. In recent years, the incidence rate has increased year by year, seriously endangering the health of patients and affecting daily life. The etiology of bronchial asthma is complex, affected by environmental factors, genetic factors and many other factors. At present, glucocorticoids and β2-receptor agonists are the first-choice drugs to control asthma attacks in clinical practice, but they cannot cure asthma, and repeated use may cause side effects such as red...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61P11/06
CPCA61K31/506
Inventor 解益新
Owner 解益新
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap